FUSE Health vs. Ro: GLP-1 Revenue Channel Comparison

Operators comparing semaglutide peptides for sale vs a built program: infrastructure, compliance posture, and margin structure broken down side by side.

Features And Capabilities	Fuse	Ro
HIPAA-Compliant Infrastructure	yes	no
White Label Operator Storefront	yes	no
Pre-built Clinical Workflows	yes	no
Semaglutide Pharmacy Routing	yes	no
Operator Revenue Ownership	yes	no
LegitScript Certified	yes	no
Operator Revenue Ownership	yes	no
Operator Revenue Ownership	yes	no

Operators Need Infrastructure. Ro Built a Brand.

Ro is a direct-to-consumer telehealth company. FUSE is the infrastructure that lets operators build their own version of that model under their own brand. The difference matters when you want to sell semaglutide programs and own the customer relationship. Before operators can serve the first patient compliantly, they need clinical intake screening for contraindications, a licensed provider network across patient geographies, pharmacy routing logic connected to dispensing and compounding partners, HIPAA infrastructure with BAA coverage across clinical and fulfillment workflows, LegitScript certification for paid advertising, and subscription and refill billing. Assembling these independently takes months. FUSE delivers all pre-configured.

Your brand, not theirs

FUSE white labels every patient touchpoint — intake forms, patient portal, prescription confirmations, refill reminders — all carrying your brand. Patients stay in your ecosystem and build loyalty with your business, not a competitor's platform.

Semaglutide routing pre-configured

Pharmacy relationships and prescription routing are structured before launch so semaglutide programs move on day one. Operators do not negotiate pharmacy contracts or monitor eligibility changes — FUSE handles routing automatically.

Refill logic built in

Subscription and refill workflows convert first-visit patients into predictable recurring revenue without manual intervention. Programs without automated refill logic see high dropout at the first manual renewal point — the most common cause of poor LTV in semaglutide programs.

Semaglutide Compliance Is an Ongoing Requirement

The regulatory landscape around semaglutide telehealth is moving. FUSE is structured to hold as policy changes rather than requiring operators to rebuild compliance infrastructure every time guidance shifts. BAA coverage spans the full prescribing and fulfillment chain — not just video or intake. State licensing logic is embedded so patients are only routed to providers licensed in their state, built into intake, not managed manually.

BAA coverage across the clinical workflow

Not just video or intake but the full prescribing and fulfillment chain. Most independent HIPAA implementations cover one component. FUSE BAA coverage is what a regulated semaglutide program requires at every touchpoint.

State licensing logic embedded

Patients are only routed to providers licensed in their state — built into intake, not managed manually per enrollment. This is what prevents prescribing compliance failures at scale as a program grows across multiple states.

A Fundamentally Different Scheduling Experience.

	With FUSE	With Ro
Launch speed	With FUSE, operators launch with clinical workflows, pharmacy routing, and intake already assembled. The infrastructure is pre-built, not custom-built.	Ro is a consumer brand. Building your own semaglutide program independently takes 6 to 12 months minimum with legal, clinical, and engineering resources.
Clinical workflows	With FUSE, semaglutide intake, provider review, and refill logic run as a single coordinated system. Automated queues handle volume without manual coordination.	Without FUSE, teams manually coordinate scheduling, pharmacy, and compliance as separate systems. Each manual step is a dropout and failure point at scale.
Compliance readiness	With FUSE, BAAs, audit logs, state licensing, and LegitScript certification are built into the platform from day one and update at the platform level when guidance shifts.	Building compliance independently adds months and leaves gaps. Compliance failures typically surface at scale when volume reveals workflow edges that were not covered.
Revenue ownership	With FUSE, operators focus on growth and customer acquisition while clinical operations run in the background. Revenue flows to the operator.	With Ro, the consumer product owns the patient relationship. Operators have no scalable channel — they are competing against the platform they considered using

Daniel Meursing

CEO

Daniel is a two-time founder who has scaled service businesses across major U.S. markets. A Y Combinator competition winner, he focuses on removing operational and regulatory barriers so operators can build and scale modern healthcare businesses.

Background: Startup Operations & Service Systems
Experience: 2x Founder, Multi-Market U.S. Scaling
Qualifications: Healthtech Market Expertise & Operational Scaling
Key Achievement: Scaled Premier Staff & Eventstaff across major U.S. markets

Fuse vs Ro